30 May 2024 - Utrecht

When a pharmaceutical company wants to market a drug, it submits the results of years of research to the MEB for review. How do we handle such a huge dossier? And more importantly, how do we assess whether these results guarantee that a drug is both effective and safe? MEB assessors and regulatory project leaders give you an insight into their work: assessing a new drug is not a matter of ticking off a checklist. It is a complex balancing of benefits and risks, performed by absolute experts. You will be challenged to think about real-world examples. Do you have what it takes to decide on patient safety?